TGF-β is a potent inducer of Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain?

Osteoarthritis and Cartilage

Volumn 23, Issue 3, 2015, Pages 478-486

  Blaney Davidson, E N ^a   van Caam, A P M ^a   Vitters, E L ^a   Bennink, M B ^a   Thijssen, E ^a   van den Berg, W B ^a   Koenders, M I ^a   van Lent, P L E M ^a   van de Loo, F A J ^a   van der Kraan, P M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cartilage; NGF; Pain; Smad; TGF

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1BETA; MESSENGER RNA; NERVE GROWTH FACTOR; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ARTHRALGIA; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BOVINE; CELL LINE; COMPLICATION; DRUG EFFECTS; GENETICS; METABOLISM; PAIN; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CARTILAGE, ARTICULAR; CATTLE; CELL LINE; CHONDROCYTES; HUMANS; INTERLEUKIN-1BETA; MICE; NERVE GROWTH FACTOR; OSTEOARTHRITIS; PAIN; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84925057071     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.12.005     Document Type: Article

References (34)

1. Fitzcharles M.A., Almahrezi A., Shir Y. Pain: understanding and challenges for the rheumatologist. Arthritis Rheum 2005, 52(12):3685-3692. Epub 2005/12/06.
2. Myers S.L., Brandt K.D., Ehlich J.W., Braunstein E.M., Shelbourne K.D., Heck D.A., et al. Synovial inflammation in patients with early osteoarthritis of the knee. JRheumatol 1990, 17(12):1662-1669. Epub 1990/12/01.
3. Lane N.E., Schnitzer T.J., Birbara C.A., Mokhtarani M., Shelton D.L., Smith M.D., et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. NEngl J Med 2010, 363(16):1521-1531. Epub 2010/10/15.
4. Bannwarth B., Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?. Drugs 2014 Apr, 74(6):619-626.
5. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. JPain Off J Am Pain Soc 2012, 13(8):790-798. Epub 2012/07/13.
6. Balanescu A.R., Feist E., Wolfram G., Davignon I., Smith M.D., Brown M.T., et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis 2014 sep, 73(9):1665-1672.
7. Spierings E.L., Fidelholtz J., Wolfram G., Smith M.D., Brown M.T., West C.R. Aphase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain 2013, 154(9):1603-1612. Epub 2013/05/28.
8. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013, 65(7):1795-1803. Epub 2013/04/05.
9. McNamee K.E., Burleigh A., Gompels L.L., Feldmann M., Allen S.J., Williams R.O., et al. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain 2010, 149(2):386-392. Epub 2010/03/31.
10. Iannone F., De Bari C., Dell'Accio F., Covelli M., Patella V., Lo Bianco G., et al. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. Rheumatology (Oxford) 2002, 41(12):1413-1418. Epub 2002/12/07.
11. Pecchi E., Priam S., Gosset M., Pigenet A., Sudre L., Laiguillon M.C., et al. Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Res Ther 2014, 16(1):R16. Epub 2014/01/21.
12. Morales T.I., Joyce M.E., Sobel M.E., Danielpour D., Roberts A.B. Transforming growth factor-beta in calf articular cartilage organ cultures: synthesis and distribution. Arch Biochem Biophys 1991, 288(2):397-405.
13. Homandberg G.A., Hui F., Wen C., Purple C., Bewsey K., Koepp H., et al. Fibronectin-fragment-induced cartilage chondrolysis is associated with release of catabolic cytokines. Biochem J 1997, 321(Pt 3):751-757. Epub 1997/02/01.
14. Pombo-Suarez M., Castano-Oreja M.T., Calaza M., Gomez-Reino J., Gonzalez A. Differential upregulation of the three transforming growth factor beta isoforms in human osteoarthritic cartilage. Ann Rheum Dis 2009, 68(4):568-571. Epub 2008/05/10.
15. Kapetanakis S., Drygiannakis I., Kazakos K., Papanas N., Kolios G., Kouroumalis E., et al. Serum TGF-beta2 and TGF-beta3 are increased and positively correlated to pain, functionality, and radiographic staging in osteoarthritis. Orthopedics 2010, 33(8). Epub 2010/08/14.
16. Takahashi N., Rieneck K., van der Kraan P.M., van Beuningen H.M., Vitters E.L., Bendtzen K., et al. Elucidation of IL-1/TGF-beta interactions in mouse chondrocyte cell line by genome-wide gene expression. Osteoarthritis Cartilage 2005, 13(5):426-438.
17. Wuerzberger-Davis S.M., Miyamoto S. TAK-ling IKK activation: "Ub" the judge. Sci Signal 2010, 3(105):pe3. Epub 2010/01/21.
18. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res 2009, 19(1):128-139. Epub 2008/12/31.
19. van Beuningen H.M., Stoop R., Buma P., Takahashi N., van der Kraan P.M., van den Berg W.B. Phenotypic differences in murine chondrocyte cell lines derived from mature articular cartilage. Osteoarthritis Cartilage 2002, 10:977-986.
20. van de Loo F.A., Veenbergen S., van den Brand B., Bennink M.B., Blaney-Davidson E., Arntz O.J., et al. Enhanced suppressor of cytokine signaling 3 in arthritic cartilage dysregulates human chondrocyte function. Arthritis Rheum 2012, 64(10):3313-3323. Epub 2012/05/12.
21. Ninomiya-Tsuji J., Kajino T., Ono K., Ohtomo T., Matsumoto M., Shiina M., et al. Aresorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. JBiol Chem 2003, 278(20):18485-18490. Epub 2003/03/08.
22. DaCosta Byfield S., Major C., Laping N.J., Roberts A.B. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004, 65(3):744-752. Epub 2004/02/24.
23. Cuny G.D., Yu P.B., Laha J.K., Xing X., Liu J.F., Lai C.S., et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorganic Med Chem Lett 2008, 18(15):4388-4392. Epub 2008/07/16.
24. Blaney Davidson E.N., Remst D.F., Vitters E.L., van Beuningen H.M., Blom A.B., Goumans M.J., et al. Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. JImmunol 2009, 182(12):7937-7945.
25. van den Bosch M.H., Blom A.B., van Lent P.L., van Beuningen H.M., Blaney Davidson E.N., van der Kraan P.M., et al. Canonical Wnt signaling skews TGF-beta signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8. Cell Signal 2014, 26(5):951-958. Epub 2014/01/28.
26. Blaney Davidson E.N., Vitters E.L., van den Berg W.B., van der Kraan P.M. TGF beta-induced cartilage repair is maintained but fibrosis is blocked in the presence of Smad7. Arthritis Res Ther 2006, 8(3):R65.
27. Manni L., Lundeberg T., Fiorito S., Bonini S., Vigneti E., Aloe L. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheumatol 2003, 21(5):617-624. Epub 2003/11/13.
28. Manni L., Aloe L. Role of IL-1 beta and TNF-alpha in the regulation of NGF in experimentally induced arthritis in mice. Rheumatol Int 1998, 18(3):97-102. Epub 1998/12/02.
29. Madej W., van Caam A., Blaney Davidson E.N., van der Kraan P.M., Buma P. Physiological and excessive mechanical compression of articular cartilage activates Smad2/3P signaling. Osteoarthritis Cartilage 2014 Jul, 22(7):1018-1025.
30. Haas S.L., Fitzner B., Jaster R., Wiercinska E., Gaitantzi H., Jesnowski R., et al. Transforming growth factor-beta induces nerve growth factor expression in pancreatic stellate cells by activation of the ALK-5 pathway. Growth Factors 2009, 27(5):289-299. Epub 2009/07/30.
31. Braunger B.M., Pielmeier S., Demmer C., Landstorfer V., Kawall D., Abramov N., et al. TGF-beta signaling protects retinal neurons from programmed cell death during the development of the mammalian eye. JNeurosci 2013, 33(35):14246-14258. Epub 2013/08/30.
32. Lindholm D., Hengerer B., Zafra F., Thoenen H. Transforming growth factor-beta 1 stimulates expression of nerve growth factor in the rat CNS. Neuroreport 1990, 1(1):9-12. Epub 1990/09/01.
33. Yu G., Fahnestock M. Differential expression of nerve growth factor transcripts in glia and neurons and their regulation by transforming growth factor-beta1. Brain Res Mol Brain Res 2002, 105(1-2):115-125. Epub 2002/10/26.
34. Yankner B.A., Shooter E.M. Nerve growth factor in the nucleus: interaction with receptors on the nuclear membrane. Proc Natl Acad Sci U S A 1979, 76(3):1269-1273. Epub 1979/03/01.